Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.verified

ARWR

Price:

$19.75

Market Cap:

$2.46B

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channe...[Read more]

Industry

Biotechnology

IPO Date

1993-12-16

Stock Exchange

NASDAQ

Ticker

ARWR

The Enterprise Value as of December 2024 (TTM) for Arrowhead Pharmaceuticals, Inc. (ARWR) is 2.87B

According to Arrowhead Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.87B. This represents a change of 2.99% compared to the average of 2.78B of the last 4 quarters.

Arrowhead Pharmaceuticals, Inc. (ARWR) Historical Enterprise Value (quarterly & annually)

How has ARWR Enterprise Value performed in the past?

The mean historical Enterprise Value of Arrowhead Pharmaceuticals, Inc. over the last ten years is 2.45B. The current 2.87B Enterprise Value has changed 11.59% with respect to the historical average. Over the past ten years (40 quarters), ARWR's Enterprise Value was at its highest in in the June 2021 quarter at 8.24B. The Enterprise Value was at its lowest in in the December 2016 quarter at 10.77M.

Quarterly (TTM)
Annual

Average

2.45B

Median

2.58B

Minimum

249.93M

Maximum

6.32B

Arrowhead Pharmaceuticals, Inc. (ARWR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Arrowhead Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 436.25%

Maximum Annual Enterprise Value = 6.32B

Minimum Annual Increase = -55.47%

Minimum Annual Enterprise Value = 249.93M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20242.73B-5.53%
20232.89B-16.49%
20223.46B-45.27%
20216.32B49.90%
20204.21B73.93%
20192.42B53.47%
20181.58B436.25%
2017294.43M-19.47%
2016365.62M46.29%
2015249.93M-55.47%

Arrowhead Pharmaceuticals, Inc. (ARWR) Average Enterprise Value

How has ARWR Enterprise Value performed in the past?

The current Enterprise Value of Arrowhead Pharmaceuticals, Inc. (ARWR) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

3.02B

5-year avg

3.92B

10-year avg

2.45B

Arrowhead Pharmaceuticals, Inc. (ARWR) Enterprise Value vs. Peers

How is ARWR’s Enterprise Value compared to its peers?

Arrowhead Pharmaceuticals, Inc.’s Enterprise Value is greater than Wave Life Sciences Ltd. (1.72B), greater than CytomX Therapeutics, Inc. (55.32M), greater than Assembly Biosciences, Inc. (67.83M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than BioMarin Pharmaceutical Inc. (12.56B), less than Incyte Corporation (12.19B), less than Ionis Pharmaceuticals, Inc. (6.81B), less than Apellis Pharmaceuticals, Inc. (4.20B), greater than ProQR Therapeutics N.V. (192.86M), greater than Annexon, Inc. (512.88M), greater than Day One Biopharmaceuticals, Inc. (859.59M), greater than Terns Pharmaceuticals, Inc. (234.86M), less than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), less than IVERIC bio, Inc. (5.13B), less than Blueprint Medicines Corporation (6.12B), less than Karuna Therapeutics, Inc. (12.43B),

Build a custom stock screener for Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arrowhead Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arrowhead Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Arrowhead Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Arrowhead Pharmaceuticals, Inc. (ARWR)?

What is the 3-year average Enterprise Value for Arrowhead Pharmaceuticals, Inc. (ARWR)?

What is the 5-year average Enterprise Value for Arrowhead Pharmaceuticals, Inc. (ARWR)?

How does the current Enterprise Value for Arrowhead Pharmaceuticals, Inc. (ARWR) compare to its historical average?